US FDA Takes Lilly’s Mounjaro, Zepbound Off Shortage List But Gives Compounding Grace Period

 
• By Sue Sutter
  
GLP-1 injection
Patients must transition away from compounded versions of Lilly's tirzepatide products in the next few months. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Litigation

More from Manufacturing